系统性癌痛干预策略对居家癌痛患者生活质量改善的初步研究

注册号:

Registration number:

ChiCTR-OIN-17012570 

最近更新日期:

Date of Last Refreshed on:

2017-09-05 00:21:28 

注册时间:

Date of Registration:

2017-09-04 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

系统性癌痛干预策略对居家癌痛患者生活质量改善的初步研究

Public title:

A pilot study on systematic interventional strategy for cancer pain to improve patients' quality of life at home

注册题目简写:

English Acronym:

研究课题的正式科学名称:

系统性癌痛干预策略对居家癌痛患者生活质量改善的初步研究

Scientific title:

A pilot study on systematic interventional strategy for cancer pain to improve patients' quality of life at home

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

姚文秀 

研究负责人:

姚文秀、马洪丽 

Applicant:

Wenxiu Yao 

Study leader:

Wenxiu Yao, Hongli Ma 

申请注册联系人电话:

Applicant telephone:

+86 18908178836

研究负责人电话:

Study leader's
telephone:

+86 18908178836,18908178872

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ywxhlx@163.com

研究负责人电子邮件:

Study leader's E-mail:

ywxhlx@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

成都市人民南路四段55号

研究负责人通讯地址:

成都市人民南路四段55号

Applicant address:

55 Section 4, Renmin Road South, Chengdu, China

Study leader's address:

55 Section 4, Renmin Road South, Chengdu, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

电子科技大学医学院附属肿瘤医院、四川省肿瘤医院&研究所、四川省癌症防治中心、四川省第二人民医院

Applicant's institution:

Affiliated Cancer Hospital of Medical School,University of Electronic Science and Technology of China,Sichuan Cancer Hospital and Institute & Cancer,The Second People's Hospital of Sichuan Province

研究负责人所在单位:

电子科技大学医学院附属肿瘤医院、四川省肿瘤医院&研究所、四川省癌症防治中心、四川省第二人民医院

Affiliation of the Leader:

Affiliated Cancer Hospital of Medical School,University of Electronic Science and Technology of China,Sichuan Cancer Hospital and Institute & Cancer,The Second People's Hospital of Sichuan Province

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SCCHEC-02-2016-001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川省肿瘤医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Sichuan Cancer Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2016-04-08 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

电子科技大学医学院附属肿瘤医院、四川省肿瘤医院&研究所、四川省癌症防治中心、四川省第二人民医院

Primary sponsor:

Affiliated Cancer Hospital of Medical School, University of Electronic Science and Technology of China, Sichuan Cancer Hospital and Institute & Cancer,The Second People's Hospital of Sichuan Province

研究实施负责(组长)单位地址:

成都市人民南路四段55号

Primary sponsor's address:

55 Section 4, Renmin Road South, Chengdu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

单位(医院):

电子科技大学医学院附属肿瘤医院 四川省肿瘤医院

具体地址:

成都市人民南路四段55号

Institution
hospital:

Sichuan Cancer Hospital and Institute

Address:

55 Section 4, Renmin Road South, Chengdu, China

经费或物资来源:

企业支持:萌蒂(中国)制药有限公司

Source(s) of funding:

Enterprise support:Mundipharma(China)Pharmaceutical CO.LTD

研究疾病:

癌痛  

Target disease:

cancer pain

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

IV期临床试验 

Study phase:

4

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

1.主要目的:评估住院期间对癌痛患者实施系统干预策略,对患者出院后生活质量改善的影响; 2.次要目的: 评估住院期间对癌痛患者实施系统干预策略,对患者出院后疼痛控制情况、症状控制情况、阿片药物用量、服药依从性等方面的作用。  

Objectives of Study:

1. Primary objective: to evaluate the effects of implementing systematic interventional strategy in patients with cancer pain during hospitalization on the improving of patients quality of life after discharge; 2. Secondary objectives: the effects of implementing systematic interventional strategy in patients with cancer pain during hospitalization on improving of pain control, symptom control, opioid dosage, medication compliance and related aspects after discharge.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1)认知功能异常;2)不能配合完成问卷者;3)试验期间服用中草药/中成药止痛者。

Exclusion criteria:

1. cognitive dysfunction;
2. inability to cooperate and complete the questionnaires;
3. Take traditional Chinese medicine / Chinese medicine for pain relief during the trial.

研究实施时间:

Study execute time:

From 2017-03-13 00:00:00 To 2018-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-04-05 00:00:00 To 2018-03-31 00:00:00

干预措施:

Interventions:

组别:

系统干预组

样本量:

30

Group:

systematic interventional group

Sample size:

干预措施:

在四川省肿瘤医院病房护理常规的基础上在出院前进行肿瘤患者癌痛自我管理训练和疼痛情绪训练

干预措施代码:

Intervention:

On the basis of conventional ward care in Sichuan Cancer Hospital, the patients with cancer pain receive training on self-management for cancer pain and emotional training before discharge.

Intervention code:

组别:

常规治疗组

样本量:

30

Group:

Routine care group

Sample size:

干预措施:

常规治疗组患者接受四川省肿瘤医院病房常规护理及护士常规的出院指导,并分发癌痛控制知识手册(包 含患者在日常生活中该如何正确服药,遇到忘记、漏服等情况该如何正确处理等)

干预措施代码:

Intervention:

Routine care

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

成都 

市(区县):

武侯区 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川省肿瘤医院 

单位级别:

三甲 

Institution
hospital:

Sichuan Cancer Hospital and Institute

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

生活质量改善情况

指标类型:

主要指标

Outcome:

quality of life(QoL) improvement

Type:

Primary indicator

测量时间点:

出院3月时

测量方法:

生活质量核心问卷

Measure time point of outcome:

at 3 months after discharge

Measure method:

Quality of Life Questionnaire-Core30,QLQ-C30

指标中文名:

疼痛控制情况

指标类型:

次要指标

Outcome:

pain control

Type:

Secondary indicator

测量时间点:

出院3月时

测量方法:

简明疼痛评估量表

Measure time point of outcome:

at 3 months after discharge

Measure method:

BPI

指标中文名:

症状控制改善情况

指标类型:

次要指标

Outcome:

Symptom control

Type:

Secondary indicator

测量时间点:

出院3月时

测量方法:

埃德蒙顿症状评估量表

Measure time point of outcome:

at 3 months after discharge

Measure method:

ESAS

指标中文名:

强阿片药物用量

指标类型:

次要指标

Outcome:

Strong opioid dosage

Type:

Secondary indicator

测量时间点:

出院3月时

测量方法:

计算出院3月时所有强阿片药物用量,并转换为吗啡总量

Measure time point of outcome:

at 3 months after discharge

Measure method:

Calculate the dosage of all strong opioids at discharge and in 3 months after discharge and convert them into total morphine doses.

指标中文名:

服药依从性

指标类型:

次要指标

Outcome:

Medication compliance

Type:

Secondary indicator

测量时间点:

出院3月时

测量方法:

Morisky用药依从性问卷

Measure time point of outcome:

at 3 months after discharge

Measure method:

Morisky Medication Adherence Questionnaires

指标中文名:

退出/中止

指标类型:

次要指标

Outcome:

Drop-out (discontinuation)

Type:

Secondary indicator

测量时间点:

出院3月时

测量方法:

没有继续试验的患者人数和退出原因分析

Measure time point of outcome:

at 3 months after discharge

Measure method:

number of discontinued patients and reason of drop-out

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过ResMan提供原始数据查询

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

IPD will be public accessable via ResMan

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Not stated

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Not stated

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2017-09-05 00:21:28